Pharma M&A – Are You Ready For The Next Round?
Contributor: Pharma IQPosted: 2/17/2012
|
Pharma merger and acquisition (M&A) activity soared back to pre-recession levels in 2011 as companies began to feel the heat of the patent cliff, new figures show. International law firm Freshfields Bruckhaus Deringer calculated the value of M&As reached $224 billion (£141 billion) last year, the highest recorded since 2007, when values hit $255 billion. Full Article » |
Connections Referrals Awareness and Presence- Chris Brogan on Social Media in Pharma
Contributor: Chris BroganPosted: 6/30/2011
|
"One you might consider is this – connections, referrals, awareness and presence. If I had to bucket separate to all the names of tools, the blogs, the twitters, the wiki’s, the whatever, what you should be doing with Social Media – your number one priority is connections. Can you connect with other people and build relationships before you need a business function to come of that, " said Chris Brogan. Full Video » |
Preventing Type 2 Diabetes in the MENA Region
Contributor: Andrea CharlesPosted: 12/20/2011
|
Diabetes is a global threat. Researchers estimate that 26.6 million people in the Middle East and North Africa currently have diabetes. Six countries in the region are among the top 10 globally with the highest prevalence of diabetes. In this interview diabetes expert Professor Peter Schwarz, talks about the alarming growth of diabetes in the MENA region and strategies for prevention and management. Full Podcast » |
Value-Based Pricing in 2012 – Is it Still Worth the Trouble?
Contributor: Stuart Carroll & Alasdair WilliamsPosted: 2/8/2012
|
As the old aphorism goes, a New Year means a new beginning. It also provides an opportunity for all of us to make New Year resolutions – promises we make to one or more lasting personal goals, projects, or the reforming of a habit. In the world of health policy, this has added meaning. The Government continues to face opposition to its NHS reforms. Full Column » |
Martyrs & Models: Early Returns from the AMNOG Era
Posted: 2/6/2012During the past few months, IQWiG has made several decisions public for recently reviewed drugs. For the first time, a body of evidence exists which can shed some light upon how restrictive and how timely access will be under the new AMNOG legislation regime in Germany. Full Whitepaper » |
Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development. This portal will enable pharmaceutical executives to make decisions on pricing and reimbursement, protect their market share, improve margins and create new opportunities in emerging markets.
-
EU Product Launch – Key Considerations for Successful Niche and Orphan Drug Product Launches
February 9, 2012
Register Now -
10th Annual Cold Chain Management & Temperature Control Summit - Canada
Hyatt Regency, Toronto, Canada
February 27- 1, 2012 -
2nd Annual Pharma Regulatory Affairs Asia
Amara Singapore Hotel, Singapore
April 25- 26, 2012 -
Cold Chain Global Forum 2012
September 17- 21, 2012
|
|
sir, we have a printing unit I want printing orders how to apply here |
Posted by: chikkegowda g | Answer this question
|
|
sir, we have a printing unit I want printing orders how to apply here |
Posted by: chikkegowda g | Answer this question
|
|
May I know the exact difference between DMF grade and non-DMF grade material? |
Posted by: sumankakimani1 | Answer this question
|
|
Hi What is the Job Profile of AREA BUSINESS MANAGER in PHARMA. |
Posted by: digvijay_singh24 | Answer this question
|
|
Hi What is the Job Profile of AREA BUSINESS MANAGER in PHARMA. |
Posted by: digvijay_singh24 | Answer this question
|
|
What is a current topic of discussion in the pharmaceutical industry that could have an impact on pharmaceutical companies? |
Posted by: charlottebooth06@hotmail.co.uk | Answer this question













Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!